Phase II First Line Atezolizumab, PacliTaxel,and Bevacizumab in mTNBC

• Research type

  Research Study

• Full title

  PHASE II CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FIRST LINE ATEZOLIZUMAB IN COMBINATION WITH PACLITAXEL AND BEVACIZUMAB (AVASTIN®) IN PATIENTS WITH ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER

• IRAS ID

  287270

• Contact name

  Melissa Phillips

• Contact email

  melissa.phillips5@nhs.net

• Sponsor organisation

  Medica Scientia Innovation Research (MedSIR)

• Eudract number

  2019-001503-20

• Clinicaltrials.gov Identifier

  NCT04408118

• Duration of Study in the UK

  2 years, 0 months, 1 days

• Research summary

  Patients with mTNBC still have a poor outcome despite advances in the fields of molecular biology and the introduction of new therapies. Several agents are under investigation in the clinical and pre-clinical setting with different targets and biomarkers designed to augment treatment.The hypothesis of this study is that the addition of atezolizumab to a bevacizumab-based chemotherapy could potentially surpass the benefit of the current standard (combination of atezolizumab and nab-paclitaxel) in mTNBC patients.
  The goal of this study is to explore the potential synergism between bevacizumab (Avastin®) and atezolizumab with standard chemotherapy for mTNBC. It is mandatory to evaluate the additive effect between bevacizumab (Avastin®) and atezolizumab in patients with mTNBC (irrespective of PD-L1 expression) considering the contribution of angiogenesis to an immunosuppressive tumor microenvironment.

• REC name

  London - Hampstead Research Ethics Committee

• REC reference

  21/LO/0527

• Date of REC Opinion

  28 Jul 2021

• REC opinion

  Further Information Favourable Opinion